Abstract:The ubiquitin–proteasome pathway plays a crucial role in the regulation of many physiological processes and in the development of a number of major human diseases, such as cancer, Alzheimer’s, Parkinson’s, diabetes, etc. As a new target, the study on the proteasome inhibitors has received much attention recently. Three-dimensional quantitative structure–activity relationship (3D-QSAR) studies using comparative molecule field analysis (CoMFA) and comparative molecule similarity indices analysis (CoMSIA) techniques were applied to analyze the binding affinity of a set of tripeptide aldehyde inhibitors of 20S proteasome. The optimal CoMFA and CoMSIA models obtained for the training set were all statistically significant with cross-validated coefficients (q2) of 0.615, 0.591 and conventional coefficients (r2) of 0.901, 0.894, respectively. These models were validated by a test set of eight molecules that were not included in the training set. The predicted correlation coefficients (r2) of CoMFA and CoMSIA are 0.944 and 0.861, respectively. The CoMFA and CoMSIA field contour maps agree well with the structural characteristics of the binding pocket of β5 subunit of 20S proteasome, which suggests that the 3D-QSAR models built in this paper can be used to guide the development of novel inhibitors of 20S proteasome.

Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Dipeptides As Novel Non-Covalent 20S Proteasome Inhibitors

Design and Synthesis of A Novel Class of Furan-Based Molecules As Potential 20s Proteasome Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Triaryl Compounds As Novel 20S Proteasome Inhibitors.

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Tripeptide Boronic Acid Proteasome Inhibitors

Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome

Synthesis and SAR Study of Novel Peptide Aldehydes As Inhibitors of 20S Proteasome

Design and Synthesis of Tripeptidyl Furylketones As Selective Inhibitors Against the Β5 Subunit of Human 20S Proteasome

3D-QSAR Studies on Tripeptide Aldehyde Inhibitors of Proteasome Using CoMFA and CoMSIA Methods

Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Design, Synthesis and Biological Evaluation of Pyrrolidinone Analogs As Potential 20S Proteasome Inhibitors

Development of novel proteasome inhibitors based on phthalazinone scaffold.

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors.

Synthesis and Biological Activity of Peptide Proline-Boronic Acids As Proteasome Inhibitors